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Summary
Intraarticular injection of dexamethasone (DEX) accelerates cartilage degradation due to the suppression of chondrocyte proliferation and
extracellular matrix formation. The present study first demonstrated the interaction between DEX and TGF, a potent growth factor for
cultured rat articular chondrocytes (CRAC), and then investigated the molecular mechanism by which DEX counteracts TGF-induced
chondrocyte proliferation and differentiation through the regulation of AP-1 activity. DEX reduced serum-deprived and TGF-stimulated cell
growth and [3H]-thymidine incorporation of CRAC. DEX also inhibited the expression of ()1 type II collagen with concomitant suppression
of the promoter activity. Transfection studies using a reporter vector with AP-1 responsive elements showed that DEX reduced
TGF-activated but not basal luciferase activities. Activation of 3TP-luc, another AP-1 responsive element containing reporter was also
blocked by DEX. GAL4-Elk1 studies revealed that DEX suppressed TGF-induced ERK activation which led to c-fos gene expression
followed by increase in AP-1 complex formation, whereas the Smad pathway was not involved in DEX-dependent negative regulation of AP-1
in a reporter assay that requires FAST1-Smad2 for the activation. DEX also eliminated TGF-induced c-fos mRNA expression and ERK
activation in Northern analysis and in vitro kinase assay, respectively. Further, DNA synthesis and transactivation of type II collagen by TGF
were inhibited by PD98059, an inhibitor of MEK. Our results indicate that DEX suppressed TGF-induced chondrocyte proliferation and type
II collagen expression, probably through selective inhibition of ERK integrated AP-1 activation. © 2000 OsteoArthritis Research Society
International
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Intraarticular injection of dexamethasone (DEX), an anti-
inflammatory glucocorticoid, is commonly used to relieve
clinical symptoms in affected osteoarthritic joints. Various
studies have demonstrated that DEX inhibits the synthesis
of matrix metalloproteases and inflammatory cytokines in
experimental osteoarthritis (OA) models.1–6 However, it is
widely recognized that repeated articular injection of DEX
potentially worsens osteoarthrosis by accelerating cartilage
degradation. Another undesirable functional property of
DEX is suppression of de novo protein synthesis of
extracellular matrix, such as type II collagen and proteo-
glycan.3,6
The molecular mechanism of DEX-involved transcrip-
tional regulation has been identified in the past decade.
DEX acts by binding to homometric glucocorticoid receptor
(GR) and transactivates target genes through a gluco-
corticoid response element. DEX also exerts a negative
regulation of expression of several genes through the
TPA responsive element (TRE) by antagonizing AP-1, a
transcriptional factor composed of Fos (c-Fos, Fra-1 and
FosB) and Jun (c-Jun, JunB and JunD) families.7–9
Although the exact mechanism of this negative regulation is
not completely understood, and there are some contradict-378ing data, it is likely that DEX antagonizes AP-1 by disrupting
protein-protein interaction or by altering the functional
domains of Fos and Jun.10–13
TGF is a growth factor stored abundantly in extra-
cellular matrix in inactive form,14,15 but once released from
the matrix in response to a variety of stimuli, TGF plays an
important role in the process of cartilage repair.16,17 In
articular chondrocytes, TGF stimulates cell growth and
production of extracellular matrix.18–20 TGF exerts its
action via a heterometric complex of serine/threonine
kinase type I and type II TGF receptors. After binding to
the receptors, TGF transmits signals through MAPK
cascade and Smad pathway.21–23 We have recently
demonstrated that among the downstream cascades of
MAPK, ERK activation is required for TGF-induced cell
growth in cultured rat articular chondrocytes (CRAC).24 We
also demonstrated that TGF immediately transactivates
c-fos gene expression through the serum responsive
element (SRE).25
Despite the long-term use of DEX intraarticularly, little
is known about the molecular mechanism underlying
DEX-mediated inhibition of chondrocyte cell growth and
matrix synthesis, including the interaction of DEX with
TGF. In this study, we first showed that DEX inhibited
TGF-induced cell growth and type II collagen expression
in CRAC. To clarify the mechanism of the interaction
between DEX and TGF, we focused on the regulation of
AP-1 activity and provided evidence for AP-1 serving as the
potential target of the interaction. We also demonstrated
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here that DEX counteracts TGF-induced cell prolifer-
ation and differentiation, presumably by interrupting ERK-
mediated c-fos gene expression and subsequent AP-1
complex formation.Results
DEX-INDUCED SUPPRESSION OF CRAC CELL GROWTH
DEX is thought to inhibit the growth of articular chondro-
cytes under in vivo and in vitro conditions. To examine
whether such suppressive effect could be reproduced in
our culture system, CRAC were incubated with three differ-
ent concentrations of DEX, with or without TGF, and cell
number was monitored for up to 36 h by WST assay. The
cell number of control CRAC at 12 h increased about
1.4-fold relative to the starting point, and remained stable at
that level until 36 h [Fig. 1(a)]. Incubation with DEX signifi-
cantly reduced cell growth in a dose-dependent manner at
all time points. TGF-stimulated cell proliferation was also
suppressed by DEX. Incubation with TGF alone for 36 h
increased the cell number to 2.2-fold of the control level,
whereas co-incubation with DEX reduced TGF-induced
cell growth in a dose-dependent manner, whereby the
highest concentration of DEX (10−4 M) reduced TGF-
induced proliferation to the control levels. Suppression of
DNA synthesis by DEX was confirmed by [3H]-thymidine
incorporation assay. Incubation of CRAC with TGF
stimulated DNA synthesis to 4.5-fold of control, but
co-culture with DEX resulted in a dose-dependent inhibition
of thymidine incorporation [Fig. 1(b)]. Consistently, theMaterials and methods
MATERIALS
Five-week-old male Sprague-Dawley (SD) rats were
purchased from Charles River Laboratories (Shizuoka,
Japan). Lipofectin Reagent, fetal bovine serum (FBS) and
DMEM were obtained from Gibco Oriental (Tokyo, Japan).
Recombinant human TGF1 was from AUSTRAL Biologi-
cals (San Ramon, CA, U.S.A.). The cell culture plates were
from Falcon (Lincoln Park, NY, U.S.A.), Corning (Corning,
NY, U.S.A.) and Costar (Cambridge, MA, U.S.A.). Luci-
ferase Assay System and -Galactosidase Enzyme Assay
were from Promega (Tokyo, Japan). PathDetect Elk1 trans-
Reporting System and pAP1-luc were from STRATAGENE
(La Jolla, CA, U.S.A.). PhosphoPlus p44/42 MAPK(Tyr204)
antibody kit and specific MEK1 Inhibitor (PD98059) were
purchased from New England Biolabs (Beverly, MA,
U.S.A.). All other reagents were obtained from Sigma
Chemical Co. (St Louis, MO, U.S.A.).CELL CULTURES
The experimental protocol was approved by the Ethics
Review Committee for Animal Experimentation of Nagasaki
University Medical School. Chondrocytes were isolated
from rat articular cartilage as described previously.18 Iso-
lated chondrocytes were cultured with DMEM which con-
tained 10% FBS, and passaged once for the experiments.CELL COUNTING
Using a Cell Counting Kit (DOJINDO, Japan), the cell
growth of CRAC was evaluated by the WST-1 method as
previously described.24 Briefly, 1×103 chondrocytes were
seeded in a 96-well plate and cultured for 48 h. After serum
starvation for 24 h, the cells were incubated with or without
TGF-1 and DEX together with a tetrazolium bromide, and
absorbance at 405 nm wavelength was measured at 12, 24
and 36 h after stimulation.DNA SYNTHESIS
Serum-starved CRAC was incubated with or without
TGF and various concentrations of DEX or PD98059 for
21 h, and [3H]-thymidine was added directly in the last 5 h.
The cells were then washed three times with ice-cold PBS,
twice with ice-cold 10% trichloroacetic acid (TCA) and
lysed with 3% SDS. The incorporated [3H]-thymidine was
measured by a liquid scintillation counter as described
previously.25NORTHERN BLOT
RNA extraction and the following Northern blot analysis
were performed as described previously.18 Twenty micro-
grams of total RNA was electrophoresed in a denatured
condition, blotted on nylon membrane and subjected tohybridization with specific probes for rat 1 type II collagen
and c-fos prepared as previously described.18,25P3TP, AP-1 AND COL2A1 LUCIFERASE ASSAY
CRAC at 80% confluence were transiently transfected by
Lipofectin as described previously.24 Twenty-four hours
later, the cells were further incubated for 24 h with or
without TGF. Cell extracts were then prepared and
luciferase activity was measured by a luminometer
(TD-2020, Turner Designs Instrument, Sunnyvale, CA,
U.S.A.). To estimate the transfection efficiency, the pCMV5-
GAL vector was cotransfected in each experiment, and
-galactosidase activity was measured at 600 nm wave-
length with ONPG as described elsewhere.26TRANS-REPORTER ASSAY OF ELK1
To detect endogenous ERK activity in vivo, the pFA–
Elk1 vector that expresses a fusion protein of the functional
domain of Elk1 following GAL4 DNA binding domain was
transiently transfected in CRAC together with the reporter
vector pFR-Luc which contains a GAL4-response element
upstream of the luciferase gene.24 Luciferase activity was
then measured as described above.IN VITRO KINASE ASSAY OF ERK
ERK activity was estimated by in vitro kinase assay as
described previously.24 Kinase reaction was performed at
30°C for 30 min in the presence of cold ATP together
with Elk1 fused to GST protein. Samples were immuno-
precipitated with glutathione-Sepharose (Pharmacia) and
subjected to SDS–PAGE. Phosphorylated Elk-1 was
immunodetected on PVDF membranes with phospho-
specific Elk1 (Ser 383) antibody.
380 Y. Miyazaki et al.: Interaction of DEX and TGF in chondrocyteshighest concentration (10−4 M), DEX completely abolished
TGF-stimulated DNA synthesis.copies of a 48-bp enhancer element from the first intron of
pro1(II) collagen gene. CRAC transiently transfected with
this construct together with pCMV5-GAL were incubated
with or without DEX together with TGF for 24 h. TGF
stimulation caused about 3.5-fold increase in luciferase
activity [Fig. 2(b)]. Incubation with DEX, however, resulted
in a dose-dependent inhibition of TGF-activated induction,
although the basal level did not change significantly. The
highest concentration of DEX (10−4 M) resulted in a com-
plete inhibition of TGF-induced activation. Considered
together, these results indicate that DEX acts as static
factor for chondrocyte proliferation and differentiation.Fig. 1. DEX suppresses the basal and TGF- induced cell growth
and DNA synthesis of CRAC. (a) Effect of various concentrations
of DEX on serum-deprived or TGF-induced CRAC cell growth.
CRAC in 96-well plates were serum-deprived for 24 h and incu-
bated with the indicated concentration of DEX with or without TGF
(5 ng/ml). Cell growth was evaluated at the indicated time intervals
by WST-1, a modified MMT assay with absorbance at 405 nm
wavelength. Each data point represents the mean±S.E.M. of six
samples. A representative example of four independent exper-
iments is shown. (b) Effect of various concentrations of DEX on
DNA synthesis by CRAC. Serum-starved CRAC was incubated
with the indicated concentrations of DEX together with (solid bars)
or without (open bars) TGF (5 ng/ml) for 24 h, and [3H]-thymidine
was incorporated in the last 5 h. Each bar represents the
mean±S.D. of four samples. Results are representative examples of
two independent experiments and shown as counts relative to the
control.Fig. 2. Suppression of ()1 type II collagen expression in CRAC by
DEX. (a) Northern blot analysis of the regulation of type II collagen
expression by DEX and TGF. CRAC were serum-deprived for
24 h, and stimulated with TGF, DEX or both for 24 h. Total RNA
was then extracted, and 20 g RNA was subjected to Northern
blotting with the indicated probes. The lower panel represents the
intensities of type II collagen relative to 28S ribosomal RNA which
was quantified by NIH Image. (b) Dose-dependent inhibition of the
promoter activity of type II collagen by DEX. CRAC were
co-transfected with 800 ng/ml of a reporter construct of type II
collagen together with 200 ng/ml of pCMV5-GAL by Lipofectin,
and cultured with (solid bars) or without (open bars) 5 ng/ml TGF
for 24 h in the presence of the indicated concentration of DEX.
Luciferase and -galactosidase activities were measured as
described in the Methods. Normalized luciferase activity is
expressed relative to the control. Each bar represents the
mean±S.E.M. of six samples. Results are a representative example
of three independent experiments.INHIBITION OF EXPRESSION OF TYPE II COLLAGEN BY DEX
To examine the effects of DEX on chondrocyte differen-
tiation, we determined the expression of type II collagen by
Northern blotting. For this purpose, 24 h serum-deprived
CRAC were incubated with or without TGF and DEX for
24 h. Incubation of CRAC with TGF resulted in about
3-fold increase in the expression of type II collagen,
whereas incubation with DEX reduced mRNA expression to
about 20% of the control [Fig. 2(a)]. Furthermore, the
increased expression of collagen mRNA by TGF was
significantly reduced to about 70% of TGF alone by
co-incubation with DEX. DEX-induced inhibition of type II
collagen mRNA expression was confirmed by the promoter
analysis using a luciferase vector which contained four
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To determine the mechanism of DEX-induced suppres-
sion of cell growth and expression of type II collagen in
CRAC, we focused on the regulation of AP-1 activity, one of
DEX targets. For this purpose, a reporter construct contain-
ing seven copies of the 6-bp AP-1 binding site was trans-
fected into CRAC and the cells were incubated with or
without DEX together with TGF for 24 h. Incubation of
CRAC with TGF resulted in a dose-dependent increase
of luciferase activity [Fig. 3(a)]. Co-incubation with DEX,
however, resulted in a significant decrease of the TGF-
induced reporter activity in a dose-dependent manner,
while the basal level was not affected. We also examined
DEX inhibition of AP-1 activity using 3TP-luc which con-
tains a PAI-1 and three copies of TRE.27 Consistently, DEX,
at concentrations higher than 10−7 M decreased TGF-
induced luciferase activity in a dose-dependent manner
[Fig. 3(b)]. These results indicate that AP-1 is a candidatePD98059 INHIBITS TGF-ENHANCED DNA SYNTHESIS AND
PROMOTER ACTIVITY OF TYPE II COLLAGEN
The functional involvement of MEK-ERK pathway in
DNA synthesis and expression of type II collagen was
evaluated using PD98059, an inhibitor of MEK. For this,
CRAC were incubated with various concentrations ofFig. 3. Inhibition of TGF-activated AP-1 by DEX. (a) Effect of DEX
on TGF-activated pAP1-Luc. CRAC were co-transfected with
700 ng/ml of pAP1-Luc and 300 ng/ml of pCMV5-GAL, and
cultured with (solid bars) or without (open bars) 5 ng/ml TGF for
24 h in the presence of the indicated concentration of DEX.
Luciferase activity is expressed relative to the control. Each bar
represents the mean±S.E.M. of six samples. Results are represen-
tative examples of three independent experiments. (b) DEX inhibits
TGF-activated p3TP-Luc. CRAC were co-transfected with
700 ng/ml of p3TP-Luc together with 300 ng/ml of pCMV5-GAL,
and cultured with (solid bars) or without (open bars) 5 ng/ml
TGF-1 for 24 h in the presence of the indicated concentration
of DEX. Luciferase activity is expressed relative to the control.
Each bar represents the mean±S.E.M. of six samples. Results are
representative example of three independent experiments.target molecule involved in the antagonistic effect of DEX
on TGF action in CRAC.REGULATION OF SMAD AND MAPK PATHWAYS BY DEX
In CRAC, TGF transduces intracellular signaling
through Smad as well as MEK-ERK pathway; the latter
cascade can transactivate the c-fos gene. Since c-Fos is a
component of AP-1 together with c-Jun, it is possible that
the inhibition of AP-1 activity by DEX was due to the
interruption of signal transmission to the ERK pathway.
However, it is also possible that DEX interferes with the
Smad pathway, which alone can transactivate TRE. There-
fore, we investigated both possibilities using GAL4-Elk1
and ARE-luc. We first examined the effect of DEX on ERK
activity by GAL4-Elk1 assay which allows evaluation of the
endogenous activity of ERK. Consistent with 3TP-luc, luci-
ferase activity induced by TGF was inhibited by DEX in a
dose-dependent manner, while the basal level was not
affected significantly [Fig. 4(a)]. Involvement of the Smad
pathway was investigated by using ARE-luc, which con-
tains three copies of activin-responsive elements.28 For the
activation of ARE-luc, expression vectors of Fast1, a
Smad2 and Smad3 binding transcriptional factor, were
cotransfected to CRAC. Although transfection with ARE
alone failed to be activated (data not shown),
co-transfection with Fast1 induced a significant increase of
luciferase activity, and in the presence of TGF the activity
was stimulated about seven-fold of the control. In contrast
to Elk-1, DEX did not affect either the basal or TGF-
stimulated luciferase activities [Fig. 4(b)]. These results
indicate that the MEK-ERK cascade of MAP kinases but
not the Smad pathway could be a potential target of
DEX-dependent inhibition of AP-1 activity.DEX INHIBITION OF ERK ACTIVITY AND C-FOS GENE EXPRESSION
To determine whether DEX-dependent inhibition of ERK
activity occurred in an early phase following TGF stimu-
lation, in vitro kinase assay was performed using the cell
lysate pretreated with various concentrations of DEX for 1 h
and stimulated with TGF for 5 min. Consistent with our
previous findings, TGF stimulation caused a rapid acti-
vation of ERK [Fig. 5(a)]. Pre-incubation with DEX, how-
ever, dramatically reduced TGF-induced kinase activity
from the lowest concentration, and completely abrogated
ERK activity at 10−7 and 10−4 M concentrations.
Similar repression was also observed by Northern blot
study of c-fos gene expression, a target gene for MEK-ERK
pathway. Pre-treatment with various concentrations of DEX
resulted in a dose-dependent decrease of TGF-induced
mRNA expression, although even the highest concen-
tration of DEX (10−4 M) reduced the expression about 50%
of the control [Fig. 5(b)]. Together with GAL4-Elk1 assay,
however, these results indicate that DEX antagonizes
TGF-induced MEK-ERK activation and subsequent c-fos
expression.
382 Y. Miyazaki et al.: Interaction of DEX and TGF in chondrocytesPD98059 with or without TGF, and [3H]-thymidine was
incorporated for the last 5 h. As expected, TGF-stimulated
DNA synthesis was inhibited by PD98059 in a dose-
dependent manner, while the basal levels were only
affected minimally [Fig. 6(a)]. Similarly, the luciferase
activity of type II collagen reporter construct stimulated by
TGF was reduced by PD98059 in a dose-dependent
manner, whereas the basal level did not change [Fig. 6(b)].a marker for chondrocyte differentiation, with concomitant
suppression of the enhancer activity. These results, com-
bined with the previous findings that DEX inhibits the
expression of types II and IX collagens and proteo-
glycan,3,6 indicate that DEX in general, is likely to act as an
inhibitor of chondrocyte cell growth and differentiation.
To investigate the mechanism of DEX-induced suppres-
sion of CRAC proliferation and differentiation, we focused
on the regulation of AP-1 activity. DEX has been shown to
trans-repress several TRE containing genes.7–9 Although
still controversial, GR seems to specifically oppose
the regulatory action by modulating the protein–proteinFig. 4. Selective inhibition of ERK cascade of MAPK but not Smad
pathway by DEX in CRAC. (a) Inhibition of TGF-activated ERK
cascade by DEX in GAL4-Elk1 trans-reporting assay. CRAC were
cotransfected with 200 ng/ml of pFA-Elk1 together with 600 ng/ml
of pFR-Luc and 200 ng/ml of pCMV5-GAL, and cultured with
(solid bars) or without (open bars) 5 ng/ml TGF for 24 h in the
presence of the indicated concentration of DEX. Luciferase activity
is expressed relative to the control. Each bar represents the
mean±S.E.M. of six samples. Results are representative example of
three independent experiments. (b) Lack of influence of DEX on
ARE-Luc activity. CRAC were co-transfected with 300 ng/ml of
ARE-Luc, 300 ng/ml of pCMV5-Fast1 and 200 ng/ml of pCMV5-
GAL, and cultured with (solid bars) or without (open bars) 5 ng/ml
TGF for 24 h in the presence of the indicated concentration of
DEX. Luciferase activity is expressed relative to the control. Each
bar represents the mean±S.E.M. of six samples. Results shown are
a representative example of three independent experiments.Fig. 5. Inhibition of TGF-activated ERK activity and c-fos gene
expression by DEX. (a) Abolishment of TGF induced in vitro ERK
activity by DEX. CRAC were serum-deprived for 24 h and pre-
treated with the indicated concentration of DEX for 1 h. Cells were
then stimulated with 5 ng/ml TGF for 5 min. Equal amounts of
total cell lysates were immunoprecipitated with anti-phospho-ERK
antibody, and in vitro kinase assays were performed at 30°C for
30 min using GST-Elk1 as a substrate. Samples were then sub-
jected to 10% SDS–PAGE, transferred to PVDF membrane and
immunoblotted with phospho-specific Elk1 (Ser 383) antibody. (b)
Inhibition of TGF-induced c-fos mRNA expression by DEX.
Serum-deprived CRAC were pre-treated first with the indicated
concentration of DEX for 30 min and then stimulated with 5 ng/ml
TGF for 30 min. 20 g total RNA was subjected to Northern blot
analysis with a rat c-fos probe. The lower panel represents the
intensities of c-fos relative to 28S ribosomal RNA which was
quantified by NIH Image.Discussion
In the present study, we first examined the interaction
between DEX and TGF on cell growth and the expression
of ()1 type II collagen mRNA using CRAC. Consistent with
previous studies,29 high concentrations of DEX (>10−7 M)
retained CRAC to static state even in the presence of
TGF. DEX also blocked the expression of type II collagen,
Osteoarthritis and Cartilage Vol. 8 No. 5 383interaction of c-Fos and c-Jun.10–13 It appears that GR can
bind directly with c-Fos and c-Jun, and interfere with their
homo-or hetero-dimerization. In our study, the activities of
both AP-1 and 3TP-luc reporters were suppressed by DEX,
indicating that DEX counteracts TGF-induced cell prolifer-
ation and differentiation through AP-1 activity. In CRAC,
however, we demonstrated that the interaction occurred
within an early phase of TGF signaling cascade rather
than targeting c-Fos and/or c-Jun itself (see below).
It is well known that activated ERK phosphorylates Elk1
that leads to transactivation of the c-fos gene expression
via SRE together with ternary complex factor.30 Over-
expression of c-Fos contributes to AP-1 activation by com-
plex formation with pre-existing c-Jun. We have previously
demonstrated in CRAC that TGF transmits signals
through only ERK but not JNK or p38MAPK of MAPKcascades, and transactivates c-fos gene through SRE.24,25
Furthermore, this specific ERK activation is required for
TGF-induced cell proliferation.24 On the other hand, it has
recently been demonstrated that Smad3 could transacti-
vate AP-1 sites by direct binding to DNA, and that this
transactivation is enhanced by the direct interaction of
Smad3 with Smad4, c-Fos and c-Jun.31 These findings
suggest that DEX exerts its negative effect by inhibiting
ERK and/or Smad signaling cascades of TGF. Therefore,
we investigated the possible involvement of these path-
ways in DEX-dependent inhibition of AP-1 activity, using
Elk-1-GAL4 and ARE-luc which reflect ERK and Smad
activities, respectively. Our results that DEX reduced ERK
activation but not that of ARE-luc, suggest that DEX selec-
tively inhibits TGF-induced MEK-ERK pathway but not
Smad pathway. Indeed, in in vitro kinase assay for ERK,
pretreatment of CRAC with DEX blocked Elk1 phosphoryl-
ation. Furthermore, c-fos expression induced by TGF was
also repressed as well. However, TGF-induced MEK
activation was inhibited by lower concentrations of DEX
compared with c-fos expression, suggesting that in addition
to MEK-ERK, other TGF receptor signaling pathways
which are independent of the cross-talk with DEX, may be
involved in the induction of c-fos gene. Alternatively, these
results implicate that DEX acts negatively toward TGF-
induced AP-1 activation through a selective inhibition of
MEK-ERK pathway. Although the significance of ERK acti-
vation for AP-1 activity has not yet been completely clarified
in CRAC, the reduced expression of c-Fos may cause an
imbalance of Fos-Jun complex formation, resulting in a
transrepression of TRE (Fig. 7). Further studies including
the identification of the exact target molecules of DEX
within MAPK are necessary to clarify the mechanism of
DEX-dependent inhibition of AP-1 activity in CRAC.
The enhancer element present in the first intron of type II
collagen contains cis-elements for Sox9, Sox6 and L-Sox5,
all of which are expressed predominantly in developing
chondrocytes and are required for full activation of the
collagen gene.32–34 Since there is no AP-1 binding site in
this region, DEX may exert its negative effect through
alteration of the functional properties of these molecules or
by transrepression of upstream regulators required for the
activation of collagen gene, rather than acting directly on
this enhancer element. Similarly, it is possible that DEX
suppression of TGF-induced cell growth was not only due
to the inhibition of MEK-ERK pathway. Other target mol-
ecules may be required for the initiation of DNA synthesis
and subsequent cell proliferation. In the present study, the
basal level of type II collagen expression was strongly
diminished by DEX compared with TGF-induced expres-
sion, while the basal levels in the promoter analysis were
less affected even in the presence of high concentrations of
DEX. This discrepancy may be explained by a mechanism
in which TGF increases both the mRNA stability and
promoter activity for type II collagen whereas DEX primarily
affects the stability of the mRNA, and there is an extensive
literature describing these functional properties in DEX and
TGF.35,36 However, DNA synthesis and the promoter
activity of type II collagen were blocked by MEK inhibitor in
a similar manner by DEX, suggesting that MEK-ERK path-
way could be, at least initially, the target molecule for DEX
to inhibit DNA synthesis and differentiation of CRAC.
In conclusion, we demonstrated in the present study that
DEX antagonized TGF-induced cell proliferation and the
expression of ()1 type II collagen in CRAC, presumably
through a trans-repression machinery leading to AP-1,
whereby the selective inhibition of ERK pathway of MAPKFig. 6. PD98059 inhibits DNA synthesis and the induction of type II
collagen promoter activity. (a) PD98059 inhibition of TGF-induced
DNA synthesis. CRAC were serum-deprived for 24 h and incu-
bated with the indicated concentrations of PD98059 together with
(solid bars) or without (open bars) TGF (5 ng/ml) for 24 h. The
incorporated [3H]-thymidine was measured, and expressed rela-
tive to the control. (b) Selective inhibition of TGF-transactivated
type II collagen luciferase activity. CRAC were co-transfected with
the reporter construct of type II collagen together with pCMV5-
GAL. Twenty-four hours after transfection, the cells were incu-
bated with the indicated concentrations of PD98059, an inhibitor of
MEK with (solid bars) or without (open bars) TGF for 24 h.
Luciferase activity is expressed relative to the control. Each bar
represents the mean±S.E.M. of six samples. Results are represen-
tative example of three independent experiments.
384 Y. Miyazaki et al.: Interaction of DEX and TGF in chondrocytescascade may be integrated in the negative regulation of
AP-1 by DEX.3. Farquhar T, Todhunter RJ, Fubini SL, Burton-Wurster
N, Lust G. Effect of methylprednisolone and mech-
anical loading on canine articular cartilage in explant
culture. Osteoarthritis Cart 1996;4:55–62.
4. Cambray GJ, Murphy G, Reynolds JJ. The effects of
dexamethasone in vitro on the production of col-
lagenase and inhibitor by synovial and cartilage
explants from the joints of rabbits with a proliferative
arthritis. Rheumatol Int 1981;1:69–72.
5. Su S, Dehnade F, Zafarullah M. Regulation of tissue
inhibitor of metalloproteinases-3 gene expression by
transforming growth factor- and dexamethasone in
bovine and human articular chondrocytes. DNA Cell
Biol 1996;15:1039–48.
6. Nakamura M, Watanabe J, Ogawa R, Kanamura S.
Immunohistochemical localization of type II and type
I collagens in articular cartilage of the femoral head of
dexamethasone-treated rats. Histochem J 1997;29:
645–54.
7. Pfahl M. Nuclear receptor/AP-1 interaction. Endocr
Rev 1993;14:651–8.
8. Karin M. The regulation of AP-1 activity by mitogen-
activated protein kinases. J Biol Chem 1995;270:
16,483–6.
9. Cato AC, Wade E. Molecular mechanisms of anti-
inflammatory action of glucocorticoids. Bioassays
1996;18:371–8.
10. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S,
Ponta H, et al. Antitumor promotion and antiinflam-
mation: down-modulation of AP-1 (Fos/Jun) activity
by glucocorticoid hormone. Cell 1990;62:1189–204.
11. Yang YH, Chambard JC, Sun YL, Smeal T, Schmidt TJ,
Drouin J, et al. Transcriptional interference between
c-Jun and the glucocorticoid receptor: mutual inhib-
ition of DNA binding due to direct protein-protein
interaction. Cell 1990;62:1205–15.
12. Schule R, Rangarajan P, Kliewer S, Ransone LJ,
Bolado J, Yang N, et al. Functional antagonism
between oncoprotein c-Jun and the glucocorticoid
receptor. Cell 1990;62:1217–26.
13. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ,
Herrlich P, et al. A distinct modulating domain in
glucocorticoid receptor monomers in the repression
of activity of the transcription factor AP-1. EMBO J
1994;13:4087–95.
14. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mech-
anism of activation of latent recombinant transform-
ing growth factor 1 by plasmin. J Cell Biol 1990;110:
1361–7.
15. Wakefield LM, Smith DM, Flanders KC, Sporn MB.
Latent transforming growth factor- from human
platelets. A high molecular weight complex contain-
ing precursor sequences. J Biol Chem 1988;263:
7646–54.
16. Glansbeek HL, van Beuningen HM, Vitters EL, van der
Kraan PM, van den Berg WB. Stimulation of articular
cartilage repair in established arthritis by local admin-
istration of transforming growth factor- into murine
knee joints. Lab Invest 1998;78:133–42.
17. Bradham DM, Horton WE Jr. In vivo cartilage formation
from growth factor modulated articular chondrocytes.
Clin Orthop 1998;2:39–49.
18. Tsukazaki T, Usa T, Matsumoto T, Enomoto H, Ohtsuru
A, Namba H, et al. Effect of transforming growth
factor- on the insulin-like growth factor-I autocrine/
paracrine axis in cultured rat articular chondrocytes.
Exp Cell Res 1994;215:9–16.Fig. 7. A schematic diagram of the effect of DEX on the TGF
signaling in CRAC. In CRAC, TGF transduces intracellular
signaling through both the MEK-ERK and Smad pathways. In this
study, DEX antagonized TGF-induced chondrocyte proliferation
and type II collagen expression through selective inhibition of
MAPK cascade leading to ERK activation and subsequent AP-1
formation.Acknowledgments
We are grateful to Dr B. Crombrugghe for the kind gift of
Col2a1-luciferase construct, Dr M. Whitman for ARE-luc
and Dr H. Namba for the helpful advice.References
1. Pelletier JP, Mineau F, Raynauld JP, Woessner JF, Jr,
Gunja-Smith Z, Martel-Pelletier J. Intraarticular
injections with methylprednisolone acetate reduce
osteoarthritic lesions in parallel with chondrocyte
stromelysin synthesis in experimental osteoarthritis.
Arthritis Rheum 1994;37:414–23.
2. Pelletier JP, DiBattista JA, Raynauld JP, Wilhelm S,
Martel-Pelletier J. The in vivo effects of intraarticular
corticosteroid injections on cartilage lesions, stro-
melysin, interleukin-1, and oncogene protein syn-
thesis in experimental osteoarthritis. Lab Invest
1995;72:578–86.
Osteoarthritis and Cartilage Vol. 8 No. 5 38519. van Osch GJ, van den Berg WB, Hunziker EB,
Hauselmann HJ. Differential effects of IGF-1 and
TGF -2 on the assembly of proteoglycans in peri-
cellular and territorial matrix by cultured bovine
articular chondrocytes. Osteoarthritis Cart 1998;6:
187–95.
20. Demoor-Fossard M, Redini F, Boittin M, Pujol JP.
Expression of decorin and biglycan by rabbit articular
chondrocytes. Effects of cytokines and phenotypic
modulation. Biochim Biophys Acta 1998;1398:179–
91.
21. Visser JA, Themmen AP. Downstream factors in trans-
forming growth factor- family signaling. Mol Cell
Endocrinol 1998;146:7–17.
22. Hoodless PA, Wrana JL. Mechanism and function of
signaling by the TGF  superfamily. Curr Top Micro-
biol Immunol 1998;228:235–72.
23. Massague J. TGF signaling: receptors, transducers,
and Mad proteins. Cell 1996;85:947–50.
24. Yonekura M, Osaki M, Hirota Y, Tsukazaki T, Miyazaki
Y, Matsumoto T, et al. Transforming growth factor-
stimulates articular chondrocyte cell growth through
p44/42 MAP kinase activation. Endocr J 1999;46:
545–53.
25. Osaki M, Tsukazaki T, Yonekura A, Miyazaki Y, Iwasaki
K, Shindo H, et al. Regulation of c-fos gene induction
and mitogenic effect of transforming growth factor-1
in rat articular chondrocyte. Endocr J 1999;46:
253–61.
26. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H,
Attisano L, Wrana JL. TbetaR1 phosphorylation of
Smad2 on Ser467 is required for Smad2-Smad4
complex formation and signaling. J Biol Chem
1997;272:27,678–85.
27. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J,
Laiho M, et al. TGF  signals through a heteromeric
protein kinase receptor complex. Cell 1992;71:
1003–14.28. Chen X, Rubock MJ, Whitman M. A transcriptional
partner for MAD proteins in TGF- signalling. Nature
1996;383:691–6.
29. Itagane Y, Inada H, Fujita K, Isshiki G. Interactions
between steroid hormones and insulin-like growth
factor-I in rabbit chondrocytes. Endocrinology
1991;128:1419–24.
30. Marais R, Wynne J, Treisman R. The SRF accessory
protein Elk-1 contains a growth factor-regulated
transcriptional activation domain. Cell 1993;73:381–93.
31. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4
cooperate with c-Jun/c-Fos to mediate TGF--
induced transcription. Nature 1998;394:909–13.
32. Lefebvre V, Zhou G, Mukhopadhyay K, Smith CN,
Zhang Z, Eberspaecher H, et al. An 18-base-pair
sequence in the mouse proalpha1(II) collagen gene
is sufficient for expression in cartilage and binds
nuclear proteins that are selectively expressed in
chondrocytes. Mol Cell Biol 1996;16:4512–23.
33. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S,
Ling KW, et al. SOX9 directly regulates the type-II
collagen gene. Nature Genet 1997;16:174–8.
34. Lefebvre V, Li P, de Crombrugghe B. A new long form
of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in
chondrogenesis and cooperatively activate the type II
collagen gene. EMBO J 1998;17:5718–33.
35. Ogata Y, Niisato N, Furuyama S, Cheifetz S, Kim RH,
et al. Transforming growth factor- 1 regulation of
bone sialoprotein gene transcription: identification of
a TGF activation element in the rat BSP gene
promoter. J Cell Biochem 1997;15:501–12.
36. Wang J, Zhu Z, Nolfo R, Elias JA. Dexamethasone
regulation of lung epithelial cell and fibroblast
interleukin-11 production. Am J Physiol 1999;276:
175–85.
